<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37604821</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>5080</StartPage><MedlinePgn>5080</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5080</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-40917-3</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis causes degeneration of motor neurons, resulting in progressive muscle weakness and impairment in motor function. Promising drug development efforts have accelerated in amyotrophic lateral sclerosis, but are constrained by a lack of objective, sensitive, and accessible outcome measures. Here we investigate the use of wearable sensors, worn on four limbs at home during natural behavior, to quantify motor function and disease progression in 376 individuals with amyotrophic lateral sclerosis. We use an analysis approach that automatically detects and characterizes submovements from passively collected accelerometer data and produces a machine-learned severity score for each limb that is independent of clinical ratings. We show that this approach produces scores that progress faster than the gold standard Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (-0.86 &#xb1; 0.70&#x2009;SD/year versus -0.73 &#xb1; 0.74&#x2009;SD/year), resulting in smaller clinical trial sample size estimates (N&#x2009;=&#x2009;76 versus N&#x2009;=&#x2009;121). This method offers an ecologically valid and scalable measure for potential use in amyotrophic lateral sclerosis trials and clinical care.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Anoopum S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-8741-0621</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. agupta@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-9493-1815</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premasiri</LastName><ForeName>Alan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0261-9953</Identifier><AffiliationInfo><Affiliation>ALS Therapy Development Institute, Watertown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2996-6418</Identifier><AffiliationInfo><Affiliation>ALS Therapy Development Institute, Watertown, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS117826</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076251" MajorTopicYN="Y">Wearable Electronic Devices</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>For the methods for extracting and characterizing submovements from wearable sensor data, a PCT (US2022/081374) was filed on December 12, 2022, titled &#x201c;System and method for clinical disorder assessment&#x201d;. An earlier US Provisional Application (Serial No. 63/288,619) was filed on December 12, 2021. The patent applicant is the institution (Massachusetts General Hospital) and inventor is Anoopum Gupta. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37604821</ArticleId><ArticleId IdType="pmc">PMC10442344</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-40917-3</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-40917-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: A review. Mol. Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2018;31:648&#x2013;654. doi: 10.1097/WCO.0000000000000594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000594</ArticleId><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:259&#x2013;265. doi: 10.3109/17482960903358865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903358865</ArticleId><ArticleId IdType="pubmed">19961263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson KA, Cudkowicz ME, Berry JD. Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all? Neurotherapeutics. 2015;12:376&#x2013;383. doi: 10.1007/s13311-015-0341-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0341-2</ArticleId><ArticleId IdType="pmc">PMC4404442</ArticleId><ArticleId IdType="pubmed">25700798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2021;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J. Neurol. Sci. 1997;152:S1&#x2013;S9. doi: 10.1016/S0022-510X(97)00237-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00237-2</ArticleId><ArticleId IdType="pubmed">9419047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013;81:1350&#x2013;1355. doi: 10.1212/WNL.0b013e3182a823e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a823e0</ArticleId><ArticleId IdType="pmc">PMC3806927</ArticleId><ArticleId IdType="pubmed">24005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, et al. Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. Ann. Clin. Transl. Neurol. 2019;6:873&#x2013;881. doi: 10.1002/acn3.770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.770</ArticleId><ArticleId IdType="pmc">PMC6529832</ArticleId><ArticleId IdType="pubmed">31139685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakers JNE, et al. Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures. Amyotroph. Lateral Scler. Frontotemporal Degener. 2022;23:500&#x2013;507. doi: 10.1080/21678421.2021.2016838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.2016838</ArticleId><ArticleId IdType="pubmed">34949141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN. Considerations for amyotrophic lateral sclerosis (ALS) clinical trial design. Neurotherapeutics. 2022;19:1180&#x2013;1192. doi: 10.1007/s13311-022-01271-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01271-2</ArticleId><ArticleId IdType="pmc">PMC9275386</ArticleId><ArticleId IdType="pubmed">35819713</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. Innovating clinical trials for amyotrophic lateral sclerosis: challenging the established order. Neurology. 2021;97:528&#x2013;536. doi: 10.1212/WNL.0000000000012545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012545</ArticleId><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="pubmed">34315786</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials a review. JAMA Neurol. 2015;72:582&#x2013;588. doi: 10.1001/jamaneurol.2014.4524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4524</ArticleId><ArticleId IdType="pmc">PMC4708881</ArticleId><ArticleId IdType="pubmed">25730665</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud C, Onnela J-P, Manji H. Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders. npj Digital Med. 2019;2:3&#x2013;6. doi: 10.1038/s41746-019-0123-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-019-0123-z</ArticleId><ArticleId IdType="pmc">PMC6550158</ArticleId><ArticleId IdType="pubmed">31304390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AS. Digital phenotyping in clinical neurology. Semin. Neurol. 2022;42:48&#x2013;59. doi: 10.1055/s-0041-1741495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1741495</ArticleId><ArticleId IdType="pmc">PMC9117425</ArticleId><ArticleId IdType="pubmed">35016250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann. Clin. Transl. Neurol. 2020;7:1148&#x2013;1157. doi: 10.1002/acn3.51096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51096</ArticleId><ArticleId IdType="pmc">PMC7359124</ArticleId><ArticleId IdType="pubmed">32515889</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira FG, et al. A machine-learning based objective measure for ALS disease severity. NPJ Digit Med. 2022;5:45. doi: 10.1038/s41746-022-00588-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-022-00588-8</ArticleId><ArticleId IdType="pmc">PMC8993812</ArticleId><ArticleId IdType="pubmed">35396385</ArticleId></ArticleIdList></Reference><Reference><Citation>Beswick E, et al. A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease. J. Neurol. 2022;269:6254&#x2013;6268. doi: 10.1007/s00415-022-11312-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11312-7</ArticleId><ArticleId IdType="pmc">PMC9363141</ArticleId><ArticleId IdType="pubmed">35945397</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. J. Neurol. 2019;266:2387&#x2013;2395. doi: 10.1007/s00415-019-09427-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09427-5</ArticleId><ArticleId IdType="pmc">PMC6765690</ArticleId><ArticleId IdType="pubmed">31187191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, A. S., Luddy, A. C., Khan, N. C., Reiling, S. &amp; Thornton, J. K. Real-life wrist movement patterns capture motor impairment in individuals with Ataxia-Telangiectasia. Cerebellum10.1007/s12311-022-01385-5. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926103</ArticleId><ArticleId IdType="pubmed">35294727</ArticleId></ArticleIdList></Reference><Reference><Citation>Eklund, N. M. et al. Real-life ankle submovements and computer mouse use reflect patient-reported function in adult ataxias. Brain Commun.5, fcad064 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10042315</ArticleId><ArticleId IdType="pubmed">36993945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. 1996;58:267&#x2013;288.</Citation></Reference><Reference><Citation>Shefner JM, et al. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87:617&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977369</ArticleId><ArticleId IdType="pubmed">27385750</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodworth, R. S. Accuracy of voluntary movement. Psychol. Rev.: Monogr. Suppl.3, i (1899).</Citation></Reference><Reference><Citation>Viviani P. Do units of motor action really exist? Exp. Brain Res. Ser. 1986;15:201&#x2013;216.</Citation></Reference><Reference><Citation>Flash T, Hochner B. Motor primitives in vertebrates and invertebrates. Curr. Opin. Neurobiol. 2005;15:660&#x2013;666. doi: 10.1016/j.conb.2005.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2005.10.011</ArticleId><ArticleId IdType="pubmed">16275056</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan N, Sternad D. Dynamic primitives of motor behavior. Biol. Cybern. 2012;106:727&#x2013;739. doi: 10.1007/s00422-012-0527-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00422-012-0527-1</ArticleId><ArticleId IdType="pmc">PMC3735361</ArticleId><ArticleId IdType="pubmed">23124919</ArticleId></ArticleIdList></Reference><Reference><Citation>von Hofsten C. Structuring of early reaching movements: a longitudinal study. J. Mot. Behav. 1991;23:280&#x2013;292. doi: 10.1080/00222895.1991.9942039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00222895.1991.9942039</ArticleId><ArticleId IdType="pubmed">14766510</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker N, Philbin DA, Fisk AD. Age-related differences in movement control: adjusting submovement structure to optimize performance. J. Gerontol. B: Psychol. Sci. Soc. Sci. 1997;52B:P40&#x2013;P53. doi: 10.1093/geronb/52B.1.P40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/52B.1.P40</ArticleId><ArticleId IdType="pubmed">9008674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer B, et al. Submovements grow larger, fewer, and more blended during stroke recovery. Mot. Control. 2004;8:472&#x2013;483. doi: 10.1123/mcj.8.4.472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/mcj.8.4.472</ArticleId><ArticleId IdType="pubmed">15585902</ArticleId></ArticleIdList></Reference><Reference><Citation>Oubre, B. et al. Decomposition of reaching movements enables detection and measurement of ataxia. Cerebellum10.1007/s12311-021-01247-6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674173</ArticleId><ArticleId IdType="pubmed">33651372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. et al. Analysis of gait sub-movements to estimate ataxia severity using ankle inertial data. IEEE Trans. Biomed. Eng.10.1109/TBME.2022.3142504 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35025733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, et al. Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss. Neurology. 1983;33:654&#x2013;657. doi: 10.1212/WNL.33.5.654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.33.5.654</ArticleId><ArticleId IdType="pubmed">6682506</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas P, Langdon P. Developing multimodal adaptation algorithm for mobility impaired users by evaluating their hand strength. Int. J. Hum.&#x2013;Computer Interact. 2012;28:576&#x2013;596. doi: 10.1080/10447318.2011.636294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10447318.2011.636294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zackowski KM, Dromerick AW, Sahrmann SA, Thach WT, Bastian AJ. How do strength, sensation, spasticity and joint individuation relate to the reaching deficits of people with chronic hemiparesis? Brain. 2004;127:1035&#x2013;1046. doi: 10.1093/brain/awh116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh116</ArticleId><ArticleId IdType="pubmed">14976070</ArticleId></ArticleIdList></Reference><Reference><Citation>Huysmans MA, Hoozemans MJM, van der Beek AJ, de Looze MP, van Die&#xeb;n JH. Submovement organization, pen pressure, and muscle activity are modulated to precision demands in 2D tracking. J. Mot. Behav. 2012;44:379&#x2013;388. doi: 10.1080/00222895.2012.727916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00222895.2012.727916</ArticleId><ArticleId IdType="pubmed">23092353</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushton DJ, Andres PL, Allred P, Baloh RH, Svendsen CN. Patients with ALS show highly correlated progression rates in left and right limb muscles. Neurology. 2017;89:196&#x2013;206. doi: 10.1212/WNL.0000000000004105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004105</ArticleId><ArticleId IdType="pmc">PMC5501935</ArticleId><ArticleId IdType="pubmed">28600459</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann, G. M. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. npj Digital Medicine3, 132 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555482</ArticleId><ArticleId IdType="pubmed">33083567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandini A, et al. Kinematic features of jaw and lips distinguish symptomatic from presymptomatic stages of bulbar decline in amyotrophic lateral sclerosis. J. Speech Lang. Hear. Res. 2018;61:1118&#x2013;1129. doi: 10.1044/2018_JSLHR-S-17-0262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2018_JSLHR-S-17-0262</ArticleId><ArticleId IdType="pmc">PMC6195078</ArticleId><ArticleId IdType="pubmed">29800359</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshghi M, et al. Rate of speech decline in individuals with amyotrophic lateral sclerosis. Sci. Rep. 2022;12:15713. doi: 10.1038/s41598-022-19651-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-19651-1</ArticleId><ArticleId IdType="pmc">PMC9489769</ArticleId><ArticleId IdType="pubmed">36127362</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, N. C., Pandey, V., Gajos, K. Z. &amp; Gupta, A. S. Free-living motor activity monitoring in Ataxia-Telangiectasia. Cerebellum10.1007/s12311-021-01306-y (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302464</ArticleId><ArticleId IdType="pubmed">34302287</ArticleId></ArticleIdList></Reference><Reference><Citation>Galland, B. C. et al. Establishing normal values for pediatric nighttime sleep measured by actigraphy: a systematic review and meta-analysis. Sleep41 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29590464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouten CV, Koekkoek KT, Verduin M, Kodde R, Janssen JD. A triaxial accelerometer and portable data processing unit for the assessment of daily physical activity. IEEE Trans. Biomed. Eng. 1997;44:136&#x2013;147. doi: 10.1109/10.554760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/10.554760</ArticleId><ArticleId IdType="pubmed">9216127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, T. P. Sample Size Determination and Power (John Wiley &amp; Sons, 2013).</Citation></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979;86:420&#x2013;428. doi: 10.1037/0033-2909.86.2.420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-2909.86.2.420</ArticleId><ArticleId IdType="pubmed">18839484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>